CRISPR Therapeutics AG (NASDAQ: CRSP) In 2025: Reward Or Shame To Investors?

In today’s recent session, 1.79 million shares of the CRISPR Therapeutics AG (NASDAQ:CRSP) have been traded, and its beta is 1.75. Most recently the company’s share price was $44.72, and it changed around $3.14 or 7.56% from the last close, which brings the market valuation of the company to $3.86B. CRSP at last check was trading at a discount to its 52-week high of $63.68, offering almost -42.4% off that amount. The share price’s 52-week low was $30.04, which indicates that the recent value has risen by an impressive 32.83% since then.

CRISPR Therapeutics AG stock received a consensus recommendation rating of Buy, based on a mean score of 1.90. If we narrow it down even further, the data shows that 1 out of 28 analysts rate the stock as a Sell; another 5 rate it as Overweight. Among the rest, 10 recommended CRSP as a Hold, whereas 12 deemed it a Buy, and 0 rated it as Underweight.

CRISPR Therapeutics AG (NASDAQ:CRSP) trade information

Instantly CRSP has been showing a green trend so far today with a performance of 7.56% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 45.60 on recent trading dayincreased the stock’s daily price by 1.93%. The company’s shares are currently up 13.63% year-to-date, but still up 4.16% over the last five days. On the other hand, CRISPR Therapeutics AG (NASDAQ:CRSP) is 15.36% up in the 30-day period.

The consensus price target as assigned by Wall Street analysts is $65, which translates to bulls needing to increase their stock price by 31.2% from its current value. Analyst projections state that CRSP is forecast to be at a low of $65 and a high of $65.

CRISPR Therapeutics AG earnings are expected to increase by -25.48% in 2025, but the outlook is positive 5.55% per year for the next five years.

CRSP Dividends

CRISPR Therapeutics AG’s next quarterly earnings report is expected to be released in July.

ARK INVESTMENT MANAGEMENT LLC, with 9.1597% or 7.78 million shares worth $420.12 million as of 2024-06-30, holds the second largest percentage of outstanding shares.